Navigation Links
Actinobac Biomed, Inc. Demonstrates In Vivo Efficacy for Psoriasis Treatment
Date:6/14/2011

NEW BRUNSWICK, N.J., June 14, 2011 /PRNewswire-USNewswire/ -- Psoriasis is a persistent, long-lasting chronic skin disease affecting 2-3 percent of the world's population or more than 125 million individuals.  For some, it is just a nuisance. For others, it is disabling.

On a continuing quest to find more effective treatment for psoriasis sufferers, an article published in the Journal of Investigative Dermatology reported that the latest data from experiments performed by Actinobac Biomed, Inc., with financial backing from Foundation Venture Capital Group, LLC, successfully demonstrated the in vivo efficacy of the company's drug candidate, Leukothera™, in treating psoriasis in a humanized mouse xenograft transplantation model.  (http://www.nature.com/jid/journal/vaop/ncurrent/abs/jid2011161a.html)

"Our results clearly show that the idea of depleting diseased white blood cells with Leukothera™ is a highly effective strategy for the treatment of psoriasis and other inflammatory diseases," said Dr. Scott Kachlany, Actinobac's founder.

The studies performed at Aarhus University Hospital in Denmark showed Leukothera™ to be as effective as or better than Genentech's once marketed agent, efalizumab (Raptiva®), even when using significantly lower drug dosage levels.  Leukothera™ is a natural biologic agent that specifically targets malignant and/or inflammatory white blood cells involved in disease.  

"We provided early seed funding to Actinobac because we are convinced that they are working on breakthrough research that will make a huge impact to thousands and thousands of people around the world suffering from a variety of ailments," said James M. Golubieski, president of Foundation Venture Capital Group (www.foundationventure.com), an affiliate of New Jersey Health Foundation.  "The publication of Dr. Kachlany's findings relative to the treatment of psoriasis is proof of that."

Actinobac Biomed, Inc. was founded in 2009 to develop commercial products based upon technology developed at the University of Medicine and Dentistry of New Jersey.  The company has exclusively licensed the rights to develop Leukothera™ as a therapeutic agent.

The current focus of Actinobac activities involves the development of pharmaceutical technologies based upon the natural biologic agent leukotoxin (Leukothera™), which targets Leukocyte Function Antigen-1 (LFA-1) on diseased white blood cells.  For the work in psoriasis and other autoimmune/inflammatory diseases, Actinobac plans to continue IND-enabling studies to test in humans shortly.

For more information or to explore ways in which to partner with Actinobac, contact them at 732-371-2694, info@actinobac.com, or visit www.actinobac.com.


'/>"/>
SOURCE Foundation Venture Capital Group, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Prototype demonstrates success of advanced new energy technology
2. EntreMeds ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients
3. Juventas Therapeutics Demonstrates JVS-100 Delivery to Patients with Heart Failure is Safe and Provides Clinical Benefit
4. New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care
5. Biocept Demonstrates Multiple Phenotypes of Circulating Tumor Cells (CTCs) in Cancer Patients
6. Dune Medicals MarginProbe™ Demonstrates Increased Positive Margin Identification Leading to Reduction in Patients Indicated for Re-excision in Landmark Lumpectomy Surgery Trial
7. Precision Therapeutics ChemoFx® Demonstrates Significant Role in Selection of Chemotherapy Doublets in Non Small Cell Lung Cancer
8. Otonomys OTO-104 Demonstrates Hearing Loss Protection and Hearing Recovery in Preclinical Studies
9. Capasso lab demonstrates highly unidirectional whispering gallery microlasers
10. Integrated Analysis Demonstrates Alpha(1)-Augmentation Therapy Significantly Reduces Loss of Lung Tissue in Patients with AAT-deficiency-related Emphysema
11. Molecular Detections Detect-Ready™ MRSA Assay Demonstrates Strong Performance In Independent Comparative Study From Leading UK Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... the trading session at 4,833.32, down 0.22%; the Dow Jones ... the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ... BIND Therapeutics Inc. (NASDAQ: BIND ). Learn more ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, ... tools designed, tuned and optimized exclusively for Okuma CNC machining centers at The ... of a collaboration among several companies with expertise in toolholding, cutting tools, machining ...
(Date:6/22/2016)... , June 22, 2016 Cell Applications, ... allow them to produce up to one billion ... lot within one week. These high-quality, consistent stem ... preparing cells and spend more time doing meaningful, ... a proprietary, high-volume manufacturing process that produces affordable, ...
Breaking Biology Technology:
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
(Date:5/24/2016)... IRVINE, Calif. , May 24, 2016 Ampronix facilitates superior patient care ... LMD3251MT  3D medical LCD display is the latest premium product recently added to ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
Breaking Biology News(10 mins):